lifestyle.newsblaze.com

Author: XORTX Therapeutics Inc.

XORTX Meets Nasdaq Continued Listing Requirements

April 21, 2026
XORTX Announces Closing of Acquisition of Vectus Kidney Anti-fibrotic Asset

April 14, 2026
XORTX Confirms Effective Date of Share Consolidation

April 2, 2026
XORTX Reports that Shareholders Approved the Share Consolidation at the Annual General Meeting

March 28, 2026
XORTX Announces Results of Annual and Special Meeting of Shareholders

March 27, 2026
XORTX Announces Share Consolidation

March 25, 2026
XORTX Reports that Shareholders Approved the Share Consolidation at the Annual General Meeting

March 24, 2026
XORTX Announces Substitute Director Nominees for its Upcoming Annual and Special Meeting of Shareholders

March 18, 2026
XORTX Reports that Independent Proxy Advisory Firms Recommend XORTX Shareholders Vote “For” the Share Consolidation

March 13, 2026
XORTX Announces Filing and Mailing of the Meeting Documents in Connection with the Annual and Special Meeting of Shareholders

March 5, 2026